Alkermes Calls ADHD Drug a Potential “Company Changer” After Phase 1b Results
Alkermes said ALKS 7290 improved adult ADHD scores in 14 days and was generally well tolerated. Phase 2 data are expected in 2027.
/ 8 items
#ALKS↓
Lilly Buys Centessa for $7.8 Billion to Fight Sleep Disorders
Eli Lilly is acquiring Centessa in a $7.8 billion deal to develop breakthrough OX2R drugs for narcolepsy, idiopathic hypersomnia, and excessive daytime sleepiness.
FDA Grants Breakthrough Status to Alkermes New Narcolepsy Drug
FDA grants Breakthrough Therapy status to alixorexton for narcolepsy type 1. Clinical trials show promising results for daytime wakefulness.
Avadel Gets Competing Bid from Lundbeck
Avadel Pharmaceuticals receives unsolicited $23/share offer from Lundbeck, competing with existing $20/share Alkermes deal. Board reviewing superior proposal.
Truist Says Alkermes’ Alixorexton Data Lacks Detail Despite Phase 2 Success
Truist comments on Alkermes’ Phase 2 Vibrance-2 trial of alixorexton in narcolepsy type 2, noting "limited" details but strong patient engagement and maintaining a Buy rating with a $50 target.
Orexin Drug Race: Centessa Shows Promise, Alkermes Stands Strong
Centessa has great sleep drug data, easing daytime sleepiness. Alkermes stock jumped 7% as its competing drug is still strong.